#USA #Bethesda #NIH #Premature Infants #HIE

Cold Treatment for Preterm Infants: Examining Effectiveness

A recent investigation into the efficacy of cooling therapy for preterm infants has produced troubling insights regarding its potential benefits. This study, funded by the National Institutes of Health (NIH) and conducted by Dr. Roger G. Faix and colleagues from the University of Utah and various neonatal research centers, has drawn attention to the risks and limitations of utilizing hypothermia treatment for vulnerable newborns.

Understanding Hypoxic Ischemic Encephalopathy (HIE)

Hypoxic ischemic encephalopathy is a type of brain damage resulting from oxygen deprivation during birth. Typically, this condition can arise from circumstances such as umbilical cord compression, uterine ruptures, or other complications that can occur around birth. In previous studies with full-term infants, cooling the body temperature to approximately 92 degrees Fahrenheit significantly reduced the risk of subsequent disability and death.

However, the latest research focused on preterm infants born between 33 and 35 weeks gestation and found that this established treatment may not deliver the same benefits. During the period from 2015 to 2020, 188 preterm infants diagnosed with HIE were closely monitored, with half receiving cooling treatment while the other half maintained normal body temperatures for comparison.

Key Findings of the Study

Upon evaluating outcomes when infants reached 18 to 22 months of age, the study revealed alarming statistics. The mortality rates and incidence of moderate to severe disabilities were notably higher among those who underwent cooling treatment. Specifically, 35% of the babies who received cooling perished or suffered from disabilities, in contrast to 29% of those who received standard care.

Worryingly, the study found that the death rate was 20% for those treated with cooling, compared to 12% among the infants who maintained normal body temperatures. This led to a staggering conclusion that preterm infants receiving cooling therapy had a 74% increased risk of being either deceased or disabled and an even higher risk of death at 87%.

Implications and Future Directions

This study raises critical questions about the use of hypothermia treatment in preterm infants. The findings emphasize the need for ongoing research to establish more effective treatment protocols for this at-risk population. Despite previously reported benefits for older neonates, these results illustrate that the application of this method for preterm infants requires thorough re-evaluation.

Furthermore, as the prevalence of utilizing cooling therapy in preterm infants is on the rise, the lack of supporting research about its effects in this demographic is concerning. Healthcare providers must stay informed and cautious when applying hypothermia treatment to such vulnerable patients.

Dr. Nahida Chaktoura, head of the Pregnancy and Perinatology Division at the NICHD, is available for comments regarding the study and its implications on clinical practices.

The detailed findings of this research are documented in the article published in JAMA Pediatrics, which highlights ongoing concerns and recommendations for future investigations into safe treatment methods for newborns with HIE.

For further information about the treatments being studied and insights into neonatal healthcare, visit the NIH website or the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Conclusion

As medical professionals and researchers dissect these findings, the emphasis remains on ensuring the safety and health of preterm infants, balancing treatment efficacy with their wellbeing, and advocating for more comprehensive research that can lead to improved outcomes in neonatal care.